

# The effect of esketamine on the hypoxic ventilatory response

<b>Submission date</b> 20/06/2023	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 27/06/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/11/2024	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Opioids and anesthetics are given to patients before surgery and have an important effect on breathing. While we know that opioids are potent respiratory depressants, including depression of the hypoxic ventilatory response (HVR; the increase in breathing caused by low blood oxygen), few human studies have addressed the effect of ketamine on the hypoxic ventilatory response. Since esketamine is frequently used to reduce opioid consumption before surgery and hypoxia following surgery is quite common, it is important to study the effect of ketamine (this study will use esketamine) on the hypoxic ventilatory response in a population of healthy male and female volunteers. In the first set of experiments, the researchers expect to observe that esketamine alone does not affect the HVR. Next, they will test whether the reduced HVR by the opioid remifentanil is restored by adding esketamine.

### Who can participate?

Healthy volunteers aged 18 - 45 years

### What does the study involve?

In part 1 of the study the researchers will infuse four esketamine doses and during each dose they will measure the HVR. In part 2, they will test the dose that effectively sustains the HVR in part 1, and will determine whether that dose is able to reverse remifentanil-induced depression of the HVR.

### What are the possible benefits and risks of participating?

Participants will not benefit from participating in this study. The benefit lies within the gained knowledge about how to treat, reverse and prevent opioid-induced respiratory depression in patients treated with opioids and people with an opioid use disorder. The burden of the study is related to the measurements and interventions. The used drugs have side effects. The application of IV lines could cause short-lasting pain and might result in a temporary, self-resolving hematoma (bruise).

### Where is the study run from?

Leiden University Medical Center (the Netherlands)

When is the study starting and how long is it expected to run for?  
February 2023 to April 2024

Who is funding the study?  
Leiden University Medical Center (the Netherlands)

Who is the main contact?  
S. C. Jansen, s.c.jansen@lumc.nl

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Simone Jansen

**ORCID ID**  
<https://orcid.org/0000-0002-1175-5877>

**Contact details**  
Albinusdreef 2  
H5-P  
Leiden  
Netherlands  
2333ZA  
+31 (0)7198638  
s.c.jansen@lumc.nl

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
2023-504229-37-00

**Protocol serial number**  
2

## Study information

**Scientific Title**  
Hypoxic ventilatory response (HVR): Effect of Esketamine

**Acronym**  
HE-o-E

**Study objectives**  
Opioids and anesthetics are given to patients perioperatively and have an important effect on breathing. While it is known that opioids are potent respiratory depressants, including depression of the hypoxic ventilatory response (HVR), few human studies addressed the effect

of ketamine on the hypoxic ventilatory response. Since esketamine is frequently used to reduce opioid consumption postoperatively and hypoxia following surgery is quite common, it is important to study the effect of ketamine (this study will use the S-enantiomer, esketamine) on the hypoxic ventilatory response in a population of healthy male and female volunteers. In the first set of experiments, the researchers expect to observe that esketamine alone does not affect the HVR. Next, they will test whether the reduced HVR by the opioid remifentanil is restored by adding esketamine. It was showed earlier that esketamine enhances remifentanil-induced depressed isohypercapnic ventilation in healthy volunteers. The researchers will do so in a randomized controlled trial of esketamine versus placebo during remifentanil infusion.

### **Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

approved 12/06/2023, Medisch-Ethische Toetsingscommissie Leiden | Den Haag | Delft (LUMC Albinusdreef 2 Secretariaat: Kamer P5-22, routenummer 953 Spreekkamer: Kamer P5-40, routenummer 953, Leiden, 2333 ZA, Netherlands; Monday +31(0)71 52 63241; Tuesday +31(0)71 52 66045; Wednesday +31(0)71 52 63003; Thursday +31(0)71 52 66963; Friday +31(0)71 52 63241; metc-ldd@lumc.nl), ref: P23.039

### **Study design**

Part 1: Single-center dose-finding study; Part 2: Single-center randomized placebo-controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Safety, Efficacy

### **Health condition(s) or problem(s) studied**

The effect of esketamine on the hypoxic ventilatory response

### **Interventions**

The study intervention is the administration of esketamine.

In part 1 of the study the researchers will infuse four esketamine doses and during each dose, they will measure the HVR: In part 1 of the study, for esketamine the dosing regimen is set at dose 0 (control condition for 60 min), followed by dose 16 (16 mg given over 60 min), dose 24 (24 mg given over 60 min) and finally dose 32 (32 mg over 60 min); all doses are per 70 kg. This dosing regimen is identical to that used earlier by (Jonkman et al. BJA 2018; <https://clinicaltrialregister.nl/nl/trial/24921>).

In part 2, the researchers will test the dose that effectively sustains the HVR in part 1, and will perform an RCT (esketamine vs placebo) to determine whether that dose is able to reverse remifentanil-induced depression of the HVR. Participants will be studied three times with at least 2 days in between study visits.

### **Intervention Type**

Drug

**Phase**

Phase III/IV

**Drug/device/biological/vaccine name(s)**

Remifentanil, esketamine

**Primary outcome(s)**

Hypoxic ventilatory response as determined from the change in ventilation and the change in oxygen saturation, ie.  $\Delta$ Ventilation/ $\Delta$ Saturation with unit L/min per % desaturation, where  $\Delta$  stands for the difference between the variable observed at baseline and observed during hypoxia. Measured through measuring minute ventilation by facemask during the exposure period (i.e. l/min/% desaturation).

**Key secondary outcome(s)**

1. Plasma esketamine concentrations over time, measured using blood samples at 0, 2, 5, 30, 60, 62, 65 and 75 min following the start of each of the esketamine infusions
2. Psychomimetic side effects assessed by the Bowdle and Bond & Lader questionnaires during hypoxic breathing

**Completion date**

23/04/2024

**Eligibility****Key inclusion criteria**

1. Aged 18 - 45 years
2. Body mass index 19-30 kg/m<sup>2</sup>
3. Ability to read and understand the subject information in the Dutch language

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

45 years

**Sex**

All

**Total final enrolment**

18

## **Key exclusion criteria**

1. A history of clinically significant (as deemed by the investigators) medical or psychiatric disease; These include: clinically significant illness or disease (e.g., psychiatric disorders, disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or any clinically significant abnormal symptom or organ impairment, as judged by the investigator, found by medical history, physical examinations or vital signs at screening
2. Any allergy to food or medication
3. Weekly alcohol intake of more than 3 units/day or more than 21 units/week in women and 5 units/day and 35 units/week in men;
4. Pregnancy or lactation
5. Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to informed consent) must have a negative urine pregnancy test prior to enrolment and must agree to use a medically acceptable means of contraception from screening through at least 1 month after the last dose of study drug. By contraception we mean for women: intrauterine device (IUD), diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation. Males who are sexually active and whose partners are females of childbearing potential must agree to use condoms
6. Participation in an investigational drug trial in the 3 months before the current study
7. Illicit drug use in the 30 days before the current study
8. A positive drug urine dipstick on the screening or study days

## **Date of first enrolment**

31/07/2023

## **Date of final enrolment**

01/01/2024

## **Locations**

### **Countries of recruitment**

Netherlands

### **Study participating centre**

**Leiden University Medical Center**

Dept. of Anesthesiology

Albinusdreef 2

Leiden

Netherlands

2333 ZA

## **Sponsor information**

### **Organisation**

Leiden University Medical Center

ROR

<https://ror.org/05xvt9f17>

## Funder(s)

### Funder type

Government

### Funder Name

Leids Universitair Medisch Centrum

### Alternative Name(s)

Leiden University Medical Center, LUMC

### Funding Body Type

Government organisation

### Funding Body Subtype

Local government

### Location

Netherlands

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Albert Dahan ([a.dahan@lumc.nl](mailto:a.dahan@lumc.nl))

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		07/11/2024	20/11/2024	Yes	No